Loading
BB
bluebird bio, Inc. Stock: price and insider trades · United States
bluebird bio, Inc.: what insiders have been doing
This page follows insider dealings at bluebird bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Cambridge, United States. The group dates from 1992. No insider at bluebird bio, Inc. has published a filing in the past twelve months. The most recent one dates from 3 June 2025.
Over the whole record (from 2016), the tally stands at no purchases and 49 sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
145
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€552,259
49 ops. · all time
Who traded when
BuySaleAndrew Obenshain4 sales
Richard A. Colvin4 sales
Thomas J. Klima2 sales
Joseph Vittiglio1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$72.1M
Gross profit-US$4.8M-7% margin
Net income-US$207.3M-287.3% margin
Last declaration on 3 June 2025
Declarations145 total
1,112 sharesCommon StockSEC:0000950170-25-081135:0
1,252 sharesCommon StockSEC:0000950170-25-081156:0
3,552 sharesCommon StockSEC:0000950170-25-081151:0
1,163 sharesCommon StockSEC:0000950170-25-081150:0
928 sharesCommon StockSEC:0000950170-25-081131:0
3,414 sharesCommon StockSEC:0000950170-25-081125:0
1,143 sharesCommon StockSEC:0000950170-25-081175:0
1,323 sharesCommon StockSEC:0000950170-25-081163:0
9,027 sharesCommon StockSEC:0000950170-25-081140:0
5,000 sharesCommon StockSEC:0000950170-25-081123:0
14,416 sharesCommon StockSEC:0000950170-25-081115:0
155 sharesCommon StockSEC:0000950170-25-081108:0
1,867 sharesCommon StockSEC:0000950170-25-081105:0
921 shares@ US$3.91941.5% of flowCommon StockSEC:0001562180-25-002088:0
584 shares@ US$3.91946.6% of flowCommon StockSEC:0001562180-25-002090:0
500 shares@ US$3.91940.3% of flowCommon StockSEC:0001562180-25-002089:0
763 shares0Common StockSEC:0001562180-25-001152:0
86 shares@ US$7.39250.3% of flowCommon StockSEC:0001562180-25-000950:0
122 shares@ US$7.39250.1% of flowCommon StockSEC:0001562180-25-000953:0
238 shares@ US$7.392528.2% of flowCommon StockSEC:0001562180-25-000951:0
64 shares@ US$7.39251.4% of flowCommon StockSEC:0001562180-25-000952:0
19 shares@ US$9.240.5% of flowCommon StockSEC:0001562180-25-000270:0
140 shares@ US$9.240.5% of flowCommon StockSEC:0001562180-25-000269:0
2,824 shares@ US$0.41733.4% of flowCommon StockSEC:0001562180-24-008361:0
971 shares@ US$0.41730.2% of flowCommon StockSEC:0001562180-24-008362:0
25 of 145 declarations
About bluebird bio, Inc.
bluebird bio, Inc. is a U.S.-based biotechnology company historically listed on the NYSE/NASDAQ ecosystem, with BLUE trading on NASDAQ before the company’s delisting. It was incorporated in 1992 and later renamed bluebird bio in 2010. The company is headquartered in Somerville, Massachusetts, United States. bluebird bio built its franchise around ex vivo gene therapy, focusing on severe genetic and rare diseases where durable, potentially curative treatment options are limited.
From a business perspective, bluebird bio’s core activities have centered on the development and commercialization of lentiviral gene therapies. Its commercial portfolio included three FDA-approved therapies in the United States: LYFGENIA for sickle cell disease, ZYNTEGLO for transfusion-dependent beta-thalassemia, and SKYSONA for cerebral adrenoleukodystrophy. These products define the company’s current value proposition: one-time, high-complexity therapies intended to address serious inherited disorders at their root cause. In practical terms, bluebird’s model combines clinical development, manufacturing expertise, patient identification, treatment-center activation, and long-term follow-up, all of which are essential in gene therapy.
Read moreShow less
Historically, the company pursued a broader pipeline that also included oncology programs, but bluebird bio later spun off its oncology assets into 2seventy bio and refocused on severe genetic disease. That strategic narrowing improved the clarity of the investment case, but it also highlighted the execution challenges inherent in this segment: regulatory complexity, high manufacturing requirements, reimbursement negotiations, and the need to build trusted treatment-center networks. bluebird competes with other gene-therapy developers, rare-disease biotechs, and, in some indications, with established standards of care where available.
Geographically, bluebird bio has been strongly U.S.-anchored, with corporate and operational functions concentrated in Massachusetts. The company previously maintained a European commercial presence, but it has pared that back materially over time, underscoring its shift toward the U.S. market. Its commercial footprint depends heavily on qualified treatment centers and payer access, making market adoption as important as scientific differentiation.
A major recent development was the company’s acquisition by Carlyle and SK Capital, which closed on June 2, 2025. As a result, bluebird bio became a private company and its shares are no longer traded on any public exchange. For investors in France, Belgium, and Switzerland, this is an important context point: BLUE is now primarily relevant as a case study in gene-therapy commercialization, strategic M&A, and the risks and rewards of highly specialized biotech platforms rather than as an active listed equity opportunity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
